TrialGynecologic oncology2018

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

Carol Aghajanian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.